ReviewClinical, cosmetic and investigational dermatology2026
Repurposing Old Drugs: Roflumilast as a Promising Therapeutic Option for Plaque Psoriasis.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pathogenic studies have revealed that phosphodiesterase 4 (PDE4) plays a key role in psoriasis inflammation. This narrative review evaluates roflumilast, a potent PDE4 inhibitor available in oral and topical formulations, as a repurposed therapeutic for plaque psoriasis. Objective: To synthesize the mechanism of action, efficacy, safety, and clinical application of roflumilast, highlighting recent evidence and its position relative to existing therapies. Methods: We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library from inception to early 2026 using keywords including "roflumilast", "PDE4 inhibitor", and "plaque psoriasis". Results: Both oral and topical formulations achieve clinically meaningful improvements in PASI and IGA scores with favorable tolerability. Conclusion: Roflumilast represents a convenient, cost-effective, and practical option, especially for sensitive sites and comorbid patients, although larger head-to-head trials against biologics are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.